Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Plasma cell 1

Conditions

Recurrence 1Multiple Myeloma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 267Magnetic Resonance Spectroscopy 218pembrolizumab 203Carboplatin 170Cisplatin 137Biopsy 136Cyclophosphamide 131Paclitaxel 120Nivolumab 110Bevacizumab 104Gemcitabine 102Radiotherapy 85Dexamethasone 77Pemetrexed 75atezolizumab 73Fluorouracil 71fludarabine 69Doxorubicin 68Leucovorin 66Docetaxel 66Radiation 65Oxaliplatin 62Rituximab 60venetoclax 58Prednisone 58Cetuximab 54durvalumab 53Vincristine 52Etoposide 51130-nm albumin-bound paclitaxel 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Fumigant 93 × 30 days × Clear all
NCT07623798 2026-06-03

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Not yet recruiting
255 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT02504489 2026-05-19

DUBLIN-3

BeyondSpring Pharmaceuticals Inc.

Phase 3 Completed
559 enrolled 32 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡